Medrol (Methylprednisolone)

Medrol, a glucocorticoid, is used to manage inflammatory and immune‑mediated disorders across several organ systems.

• Asthma exacerbations: reduces airway inflammation, improving airflow and symptom control.
• Chronic obstructive pulmonary disease (COPD) flare‑ups: diminishes pulmonary inflammation, aiding breathing function.
• Severe allergic reactions: suppresses hypersensitivity responses, limiting swelling and airway compromise.
• Rheumatoid arthritis and other inflammatory rheumatic diseases: alleviates joint inflammation, pain and stiffness.
• Dermatologic inflammatory conditions: controls skin inflammation such as eczema or psoriasis flares.
• Autoimmune disorders: modulates immune activity to reduce disease activity in conditions like systemic lupus erythematosus.

• Methylprednisolone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and interacts with glucocorticoid response elements on DNA. This alters transcription of multiple genes, up‑regulating anti‑inflammatory proteins (e.g., annexin‑1) and down‑regulating pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6 and tumor necrosis factor‑α, resulting in broad anti‑inflammatory and immunosuppressive effects. It also stabilizes lysosomal membranes, reducing tissue damage.

Methylprednisolone may cause a range of adverse reactions, varying from mild and transient to serious and potentially life‑threatening.

Common Side Effects

• Increased appetite: may lead to weight gain.
• Fluid retention or mild edema: swelling of ankles or hands.
• Elevated blood glucose: can worsen diabetes control.
• Mood changes such as irritability: includes anxiety or insomnia.
• Insomnia: difficulty sleeping.

Serious or Rare Side Effects

• Severe infection risk: reduced immune response may predispose to bacterial, viral or fungal infections.
• Osteoporosis or bone fractures: long‑term use can decrease bone mineral density.
• Adrenal suppression: may cause cortisol deficiency on abrupt discontinuation.

When prescribing Medrol, clinicians should consider several precautionary measures to minimize risk.

• Assess infection risk: evaluate for active or latent infections before initiating therapy.
• Monitor blood glucose: check glucose levels regularly in diabetic or pre‑diabetic patients.
• Screen for osteoporosis: consider bone density testing for long‑term users.
• Taper dose gradually: avoid abrupt discontinuation to prevent adrenal insufficiency.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Methylprednisolone can interact with other medicines, altering their effects or increasing toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce steroid levels and efficacy.
• Live vaccines: increased risk of disseminated infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): steroids may enhance anticoagulant effect, requiring INR monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use raises gastrointestinal ulcer risk.
• Diabetic agents: steroids can raise blood glucose, necessitating dose adjustments.